The International HapMap Consortium recently completed genotyping over 3.8 million single nucleotide polymorphisms (SNPs) in three major populations, and the results of studying patterns of linkage disequilibrium indicate that characterization of 300,000-500,000 tag SNPs is sufficient to provide good genomic coverage for linkage-disequilibrium-based association studies in many populations. These whole-genome association studies will be used to dissect the genetics of complex diseases and pharmacogenomic drug responses. As such, the development of a cost-effective genotyping platform that can assay hundred of thousands of SNPs across thousands of samples is essential. In this review, we describe the development of a whole-genome genotyping (WGG) assay that enables unconstrained SNP selection and effectively unlimited multiplexing from a single sample preparation. The development of WGG in concert with high-density BeadChips™ has enabled the creation of three different high-density SNP genotyping BeadChips: the Sentrix™ Human-1 Genotyping BeadChip containing over 109,000 exon-centric SNPs; the HumanHap300 BeadChip containing over 317,000 tag SNPs, and the HumanHap550 Beadchip containing over 550,000 tag SNPs.
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The goal of pharmacogenomics is to use individual's genetic information to improve patient diagnosis, prognosis, and therapeutic intervention [1] . Genetic differences between individuals within a population underlie an individual's predisposition to maintain health, develop disease, and respond efficaciously or adversely to drug therapy [2] [3] [4] . Human genetic variation is characterized, in part, by the presence of over 10 million relatively common, single nucleotide polymorphisms (SNPs) in the human genome. The linkage disequilibrium (LD) patterns observed in human population reveal a blocklike structure; SNPs within a high LD region (termed haploype block) tend to be transmitted together from generation to generation [5, 6] . As such, a set of tag SNPs that serve as proxies for other SNPs can be chosen based on levels of correlation between their alleles [7, 8] . The use of tag SNPs greatly reduces the genotyping burden in association studies, since a fewer number of tag SNPs need to be genotyped while maintaining the same information and power as if one had genotyped a much larger number of random SNPs [9] . The objective of the HapMap project was to delineate the haplotype block structure of the human genome and provide data for the identification of tag SNPs across multiple populations with ancestry from parts of Africa, Asia and Europe. The HapMap project completed both Phase I and II in late 2005 [10] ; the resulting haplotype analysis of the data indicates that approximately 300,000 tag SNPs will provide good coverage for the European (CEU, Utah residents with ancestry from Northern and Western Europe) and Asian populations (CHB, Han Chinese in Beijing, China and JPT, Japanese in Tokyo, Japan), and a set of over 500,000 tag SNPs will provide improved coverage for European and Asian populations and good coverage for an African population (YRI, Yoruba in Ibadan, Nigeria) [10] .
Infinium whole-genome genotyping platform We developed a whole-genome genotyping technology, known as the Infinium™ assay ( Figure 1A) , to enable genotyping of hundreds of thousand of SNPs on a single BeadChip™ substrate (slide). The whole-genome genotyping assay was developed to mirror the scalability of an array-based gene expression assay in which a simple singletube sample preparation allows readout of an entire transcriptome [11] . To make the assay inherently scalable, the Infinium assay employs a direct hybridization of a single-tube whole-genome amplified (WGA) DNA sample to an array of oligonucleotide capture probes (50-mers). The WGA step amplifies the input genomic DNA (gDNA) present at a few hundred nanograms by over 1000×, leading to hundreds of micrograms of WGA product. This high concentration of target drives the hybridization capture of the target loci to the probes on the array. Following capture of the target loci, an array-based enzymatic SNP scoring step is used to generate the genotype. The partitioning of the assay into an independent capture step and separate SNP scoring step allows greatly enhanced discrimination, especially through the use of highly-specific DNA enzymes such as polymerases or ligases. Finally, after the extension step, a signal amplification step is used to boost the overall signal:noise of the assay.
Infinium I & II whole-genome genotyping biochemistry
Following hybridization of fragmented WGA DNA to the BeadChip, it undergoes an arraybased extension-staining protocol. For enzymatic SNP scoring, we employ two forms of arraybased primer extension reaction using either a single-color allele-specific primer extension (ASPE) format [11, 12] , known as Infinium I, or a A. Genomic DNA is WGA, fragmented and denatured. This product is hybridized to an array of 50-mer capture probes. A primer-extension-based SNP scoring step is performed directly on the array surface. The separation of the capture step from the SNP scoring step allows efficient target capture while generating good discrimination between alleles. After extension, the array is stained and read out using standard detection methods. B. Infinium I ASPE biochemistry employing two beads and one color per SNP assay. Polymerase extension under optimized conditions leads to preferential extension of the probes matched at their 3' ends to the hybridized target. C. Infinium II SBE biochemistry employing one bead and two colors per SNP assay. Incorporation of ddNTPs bearing two different haptens and subsequent two-channel immunohistochemistry staining enables the two-color readout. ASPE: Allele-specific primer extension; DNP: Deoxyribonucleoprotein; gDNA: Genomic DNA; SBE: Single base extension; SNP: Single nucleotide polymorphism; WGA: Whole-genome amplified. 
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Whole-genome genotyping of haplotype tag SNPs -TECHNOLOGY REPORT dual-color single base extension (SBE) format [13, 14] known as Infinium II ( Figure 1B and C). In the ASPE format, two probe pairs (designated bead types A and B corresponding to A and B alleles) are used per locus. The two probes are identical except at their terminal 3´ base, which is designed to perfectly match one allele or the other. Perfect 3´ complementarity between the probe and hybridized target allows efficient primer extension, whereas a single base mismatch at this site greatly reduces extension efficiency.
In the other format, SBE, a single probe twocolor assay is employed and SNP alleles are distinguished by incorporation of two-color differentially-labeled nucleotides. SBE has several advantages over ASPE:
• SBE requires half the number of array elements (bead types)
• SBE biochemistry is inherently more robust since it is an endpoint rather than kinetic measurement as in ASPE
• Less redundancy is required since allelic ratios (A allele vs B allele) are computed by ratioing two colors on a single bead, rather than ratioing across bead types
The assay requires only a single bead type and two color channels to detect 83% of common biallelic SNPs (i.e., A/C, A/G, T/C and T/G). The remaining 17% of SNPs (A/T and C/G) can be assayed by Infinium I assays, and by using SBE biochemistry as described by Steemers and colleagues, both assays can be run simultaneously on the same BeadChip allowing access to 100% of SNPs [14] .
High-density BeadChips
In order to exploit the whole-genome scalability of the above described Infinium assay, we developed high-density patterned slide substrates called BeadChips created through micro-electro-mechanical systems (MEMS)-manufactured processes. Our current BeadChip design contains 12 stripes or regions of patterned high-density 3 µm wells (Figure 2) . Each stripe region holds over 1.1 million beads for a total of over 13 million beads per BeadChip. Each stripe is loaded with a different bead pool with a complexity of up to 60,000 bead types for a total of up to 720,000 different bead types across the BeadChip with an average redundancy of approximately 20 beads per bead type. Following bead assembly the BeadChips undergo a decoding process by which the identity of each bead on the array is determined [14] . We currently decode up to 60,000 bead types per section; however, this number can be further scaled by using smaller beads and decoding pools of higher complexity. Both the HumanHap300 (> 317,000 SNPs) and the HumanHap550 (> 550,000 SNPs) BeadChips use only 10 out of 12 stripes with the remaining stripes reserved for augmentation or customized applications.
Tag single nucleotide polymorphism selection
We took advantage of the tag SNP concept and used data from the HapMap Phase I data to intelligently select particular SNPs that would provide maximal coverage of the human genome. The content of the HumanHap300 was generated by selecting common SNPs with a minor allele frequency (MAF) greater than or equal to 5% in the Centre d'etude du polymorphisme humaine (CEPH) population (CEU), binning the SNPs that are in high LD (r 2 statistic) with one another using LdSelect [16, 17] , and selecting the tag SNP with the highest design score for each bin. The design score is predictive of assay conversion success and is based upon a combination of theoretical and heuristic rules correlating with Infinium assay success. The r 2 statistic provides a measure of how effectively a particular tag SNP proxies for a SNP in the same bin. We also included approximately 7300 nonsynonymous SNPs and approximately 1500 tag SNPs from high-density SNP data for the major histocompatibility complex (MHC) region. In total, the HumanHap300 contains over 317,000 tag SNPs from the Phase I HapMap. This set of SNPs provides good genomic coverage as assessed by its coverage of the entire set of Phase I and II HapMap SNPs (Figure 3) . At an r 2 value of more than 0.8 the content of this chip covers approximately 80% of other common SNPs in the CEU population, approximately 68% of common SNPs in the Han Chinese and Japanese (CHB/JPT) population, and approximately 34% of common SNPs in the Yoruba (YRI) population. Coverage for the YRI population common SNPs is low because the YRI population is much more diverse than the CEU and CHB/JPT populations. The tag SNPs selected for the HumanHap550 product will contain all the SNPs in the HumanHap300, plus additional SNPs to improve the coverage in all populations, in particular the CHB/JPT and YRI populations.
Genotyping over 317,000 SNPs on a single HumanHap 300 BeadChip
We developed a total of 317,503 tag SNPs contained within 10 of the 12 sections present on our high-density BeadChip format. Genotyping quality was assessed by analyzing 127 DNA samples of diverse origin (CEU, CHB, JPT and YRI) containing 25 parent-parent-child trios and 15 replicates. Figure 4A shows a genotyping plot from over 317,000 SNP genotypes from a single sample assayed on the HumanHap300 BeadChip. The distribution of theta values (allelic intensity ratios) is remarkable in that the 317,000 loci distribute into three natural clusters (baseline separated) corresponding to the three possible genotype categories. An example of a GenoPlot with a median cluster quality is shown in Figure 4B . Call rate, reproducibility, accuracy and heritability were all consistent with high performance genotyping (Table 1) . The consistently high call rates and genotyping performance can be attributed to the development of robust automated procedures and the use of preformulated reagents. Additionally, the inherent simplicity of assay design coupled with robust genotyping biochemistry (ASPE or SBE) contributes to overall data quality.
This HumanHap300 product will be followed with the HumanHap550 which is derived from a full analysis of the HapMap Phase I and II data 
Assay automation
We have automated the Infinium whole-genome genotyping (WGG) assay using a Tecan GenePaint™ (Tecan, Zurich, Switzerland) system and formulated reagents into aliquoted single use tubes. Tecan's GenePaint slide processing platform provides an efficient reagent delivery system, a temperature-controlled environment, and easy robotic automation ( Figure 5 ). The Tecan GenePaint system employs a capillary gap TeFlow chamber ( Figure 5A ) to enable easy washing and reagent exchanges on the BeadChip. The capillary gap is created by a 70 µm spacer, and reagent is always maintained within the gap by capillary action. BeadChips are positioned vertically on a temperature-controlled Tecan Chamber rack ( Figure 5B ). Reagent delivery is performed by simple robotic operation in which reagents are dispensed into the flow cell reservoir. Reagents flow through the TeFlow chamber and displace existing reagents by gravity flow. Reagents are continually dispensed and displaced during each successive step in the process. All reagent transfer steps including pipetting of wash solutions, blocking mixes, extension reagents, and staining reagents are performed on the Tecan robot bed. In summary, the complete assay has been automated from sample preparation through to slide processing posthybridization.
Infinium workflow
The On day 2, the amplified DNA is fragmented (approximately 500 bp) by a highly robust, endpoint fragmentation procedure (step 3). Next, the DNA sample is isopropanol precipitated, spun down, and resuspended directly in hybridization solution using moderate agitation (step 4). In preparation for hybridization, the Illumina Beadchips are assembled into a TeFlow capillary flow chamber (step 5). DNA samples are added robotically from the sample plate. LIMS tracking ensures proper sample-to-slide association. Hybridization proceeds overnight (i.e., 16-20 hr) and occurs between the target genomic DNA (gDNA) and oligonucleotide capture probes (50 mer) covalently attached to the bead surface (step 6).
On day 3, Beadchips are processed through a probe extension and staining procedure (step 7). After hybridization, the Beadchip is washed to remove unhybridized and nonspecifically hybridized gDNA targets and blocked to reduce nonspecific signal and chemical noise. Next, beadbased probes are extended 5´-3´ in an allele-specific manner by a DNA polymerase that incorporates a single hapten-labeled dideoxynucleotide (ddNTP -biotin and DNP are used), whose identity is determined by the allele present in the captured target sequence. Following extension, the hybridized targets, which may also contain incorporated labels, are removed to reduce nonspecific background noise. Incorporated haptens are converted to fluorescent signal by a multilevel immunohistochemistry staining system, which maximizes the signal:noise ratio. Finally, BeadChips are coated with a protectant to maintain stability of the fluorescent dyes during prolonged exposure to ambient conditions. The BeadChips are imaged using a two-color, confocal laser scanner with a resolution of 0.8 µm (step 8). Image files are automatically registered, extracted and bead-type intensities summarized by Illumina BeadScan software. Next, data files are imported into the Illumina BeadStudio genotyping package where genotypes are auto-called, based on an Illumina-supplied cluster file. The BeadStudio software offers simple and efficient generation of genotype summary reports, integral for whole-genome association studies, as well as a powerful genome browser and chromosome viewer that supports loss-of-heterozygosity (LOH) and copy number analysis.
Conclusions
We have combined our Infinium genotyping assay with our high-density BeadChips to create an automated, single tube/slide, high-quality genotyping system. The Infinium assay consists of four modular steps consisting of whole-genome amplification, hybridization to a 'gene expression-like' capture array, array-based enzymatic SNP scoring, and signal amplification. This simple system is intrinsically scalable, adaptable and able to target almost any SNP of interest. As such, it provided a powerful solution to the development of a highlyparallelized assay platform for querying haplotype tag SNPs. Finally, the Infinium assay has been automated using the Tecan GenePaint slide processing system. This automation contributes to the ease of use, robustness and LIMs tracking capability of the Infinium assay. Based upon this platform, we have developed two tag SNP products, a Human Hap300 BeadChip that provides good genomic coverage of the CEU and CHB/JPT populations and a HumanHap550 BeadChip with enhanced coverage of all populations including the YRI. Genotyping performance of these products is industry-leading with high call rates, reproducibility and concordance. In summary, the ability to conduct whole-genome association studies is now at hand with the combination of tag SNPs and WGG technology.
Outlook WGG is an enabling technology that has reduced the cost of genotyping below 0.25 cent per genotype. This cost structure is ushering in a 'gold rush' of whole-genome association studies aimed at identifying the underlying genetic components of disease. This approach is also being applied to pharmacogenetics to identify the genetic components of drug efficacy and safety.
In the future, it may become the norm for every clinical trial to employ tag SNP WGG, and in fact, the US FDA may require such submissions with a new drug approval (NDA). Putting pharmacogenomics costs in perspective, the use of tag SNP WGG for all clinical samples represents a small fraction of the total cost of bringing a new drug to market, especially when pharmacogenomics can potentially be used to rescue a drug that otherwise might fail a clinical trial due to adverse or inefficacious responses.
The authors foresee that the use of tag SNP WGG in pharmacogenomics can potentially transform drug development and therapy. Billions of dollars are spent on inefficacious pharmaceutical intervention, since many drugs have an efficacy rate of only 60% or less. In addition, WGG studies can identify adverse drug reactions The entire Infinium II WGG assay takes a total of approximately 3 days to complete with minimal hands-on time (using automation). In day 1, gDNA is amplified in an overnight whole-genome amplification reaction. On day 2, the amplified product is fragmented, precipitated, resuspended in hybridization buffer, and placed upon a BeadChip for an overnight hybridization step. In day 3, the BeadChip is X-stain processed on the Tecan GenePaint™ slide processing system including washing, primer extension (SBE), and signal amplification (staining). Finally, the BeadChips are dried, protected, and then imaged on Illumina's BeadArray Reader. gDNA: Denomic DNA; SBE: Single base extension; WGG: Whole-genome genotyping. (ADRs) in patients, making drugs safer. Given that worldwide, over US$450 billion a year [101] is spent on prescription drugs, one can estimate that almost $200 billion a year is ineffectively spent with the added burden of ADRs. The use of WGG to genetically identify those individuals who are either likely to be unresponsive to drug therapy or suffer an ADR should greatly improve healthcare and reduce the failure rate of bringing new drugs to market.
